drugset / Trial / NCT07175389
JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Serplulimab in patients with pancreatic cancer after standard treatment failure.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2027-09-01
- Completion
- 2027-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JDB153 | Unknown | 500 mg | Oral |
| Subject | JDB153 | Unknown | 600 mg | Oral |
| Subject | Serplulimab | Monoclonal antibody | 200 mg | Intravenous |